Pegulicianine Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 39 mg
Reference Brands: Generic formulations marketed under different names
Category:
Oncology Cancer Care
Pegulicianine is available in Injection
and strengths such as 39 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pegulicianine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pegulicianine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Lorlatinib, marketed under the brand name Lorbrena in the USA, Canada, and Japan, and Lorviqua in the European Union, is an orally administered anti-cancer medication developed by Pfizer. It is used for the treatment of non-small cell lung cancer (NSCLC) in patients whose tumors are ALK-positive or ROS1-positive. Lorlatinib functions as an ATP-competitive inhibitor of the receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1), which are critical for cancer cell growth and survival. By selectively inhibiting these kinases, Lorlatinib disrupts ALK- and ROS1-mediated signaling pathways, suppressing tumor cell proliferation in ALK- and ROS1-overexpressing cancer cells.
A key feature of Lorlatinib is its ability to cross the blood-brain barrier, making it effective against central nervous system metastases often seen in ALK-positive NSCLC. Administered orally in tablet form, Lorlatinib offers a targeted therapy option for patients who have previously received other ALK-directed treatments. Its mechanism allows for precise inhibition of tumor growth while minimizing systemic exposure, making it a preferred therapy for advanced lung cancer with specific genetic mutations. Lorlatinib represents an important advancement in personalized oncology care, providing both efficacy and safety for patients with ALK- or ROS1-driven tumors.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing